Thought Leadership on RBQM

ACRO’s February 2023 RBQM Summary Report highlights the key takeaways from ACRO’s RBQM survey, outlining the current state of RBM & RBQM in the clinical research industry.

• Risk-Based Monitoring in Clinical Trials: Summary Report 

In January 2023, ACRO released a third publication on the takeaways from our 2021 landscape survey of RBM and RBQM implementation. This report builds on the results from our 2019 and 2020 survey findings.

• Risk-Based Monitoring in Clinical Trials: 2021 Update

In March 2022, ACRO released a new analytical report on the takeaways from our 2020 landscape survey of RBM and RBQM implementation. This report builds on the results from our 2019 survey findings. 

• Risk-Based Monitoring in Clinical Trials: Increased Adoption Throughout 2020

In April 2021, ACRO released a new analytical report highlighting significant shifts in remote monitoring during COVID-19.

• Risk-based Monitoring in Clinical Trials: Past, Present & Future

In October 2019, ACRO released two white papers featuring insights and recommendations for further implementation of RBM.

• Risk-Based Quality Management (RBQM) – A Collaborative Approach to Holistic Clinical Trial Oversight
• Establishing Risk-Based Monitoring within a Quality-Based System as “Best Practice” for Clinical Studies

Advancing RBM

ACRO members have made significant investments to advance RBM. From reshaping and bolstering their workforce to support this growth to developing diverse, cross-functional solutions, to incorporating new and updated methods to support and improve RBM across clinical research.

Explore some of ACRO’s additional RBM resources:

• INFOGRAPHIC: RBQM Trial Evaluation
• WEBINAR SERIES: How much do you know about Risk-Based Monitoring (RBM)?
• ACRO Comments on FDA Guidance
• The Risk-Based Monitoring Landscape in 2018
• INFOGRAPHIC: Data Quality and Patient Safety
• PANEL: Risk-Based Monitoring in Clinical Trials: An Evolution of Practices During the COVID Pandemic (DIA)